Evidence map›Paper›PMID 36291951›Full record

ArticleCancers2022

Stereotactic Body Radiotherapy Boost with the CyberKnife for Locally Advanced Cervical Cancer: Dosimetric Analysis and Potential Clinical Benefits.

Jiaxiang Gao, Benhua Xu, Yibin Lin, Zhenhang Xu, Miaoyun Huang, Xiaobo Li, Xiaodong Wu, Yuangui Chen

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Jiaxiang GaoDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Benhua XuDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Yibin LinDepartments of Gynecology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350014, China.
Zhenhang XuDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Miaoyun HuangDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Xiaobo LiDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Xiaodong WuDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Yuangui ChenDepartment of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350001, China.ORCID 0000-0003-4817-5224
Fujian Medical University · CN

Funding

Joint Funds for the Innovation of Science and Technology, Fujian Province 2018Y9001Natural Science Foundation of Fujian Province 2021J01740
6 · The paper itself

Abstract

(1) Aim: To compare the treatment plans of stereotactic body radiotherapy (SBRT) with CyberKnife (CK) and high-dose-rate (HDR) intracavitary/interstitial brachytherapy (IC/ISBT) and examine the feasibility of CK-SBRT as a viable alternative to BT in patients with locally advanced cervical cancer (LACC). (2) Methods: A BT plan of 28 Gy in four fractions delivered previously to 20 patients with LACC was compared with a CK plan based on the same CT images with structures delineation for BT. The SBRT treatment plan was further divided according to two different approaches, with the high-risk planning target volume (HR-PTV) defined by the high-risk clinical target volume (HR-CTV) without and with a 5 mm margin, which were named CK-CTV plan and CK-PTV plan, respectively. The dose distributions and dosimetric parameters of the target volumes and organs at risk (OARs) were recorded and compared for the three boost plans. Radiobiological metrics were calculated based on the EUD for the hybrid plans. Additionally, the relationship between tumor volume and tolerance doses for the OARs in the BT plan and CK-PTV plan was investigated. (3) Results: Target coverage was better with the CK plan than with the BT plan, as the D95%, D98%, HI and CI of the CK-CTV plan and CK-PTV plan were higher than those of the BT plan; an exception was the D50%. Similarly, the TCP of the target was also significantly in favor of the CK hybrid plans (p < 0.01). For the OARs, the CK-CTV plan was superior to the BT plan as regards the rectum D2cc, bladder D2cc and bladder Dmax. The CK-PTV plan could achieve dosimetric parameters comparable to those of the BT plan for OARs concerning the small residual tumor volume. The NTCP of the rectum for the WPI+CK-CTV plans was significantly lower than that of the WPI+BT plans (p < 0.01). (4) Conclusions: CK-based SBRT can achieve better target coverage, dose sparing for the OARs and radiobiological effects compared with the BT plan for tumors that are not excessively large. CK-based SBRT could be an alternative option to administer a radiation boost for patients with LACC.

Indexed as

CyberKnifehigh-dose-rateinterstitial brachytherapylocally advanced cervical cancerNTCPradiobiologystereotactic body radiotherapy

Identifiers

PMID36291951
PMCPMC9600637
OpenAlexW4307122014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.